DALLAS – Aug. 09, 2022 – Over the first year of the COVID-19 pandemic, almost 30% of patients with obesity gained more than 5% of their body weight, and 1 in 7 gained more than 10%.
ProSciento, Inc., a specialty clinical research organization (CRO) focused exclusively on diabetes, obesity, non-alcoholic steatohepatitis (NASH), and related metabolic diseases, has announced the appointment of Michelle Mazuranic, PhD, MSM, RD, as Vice President of Medical and Regulatory Affairs .
16 April 2021 COVID-19 patients who are overweight or obese have more severe symptoms and are highly likely to require invasive respiratory support, according to a new international study. The research, led by The University of Queensland and the Murdoch Children’s Research Institute (MCRI), found obese patients had a 73 per cent greater chance of needing invasive mechanical ventilation and were more likely to require oxygen. UQ’s Dr Kirsty Short said similar but more modest results were seen in overweight patients, but no link was found between being overweight or obese and dying in hospital from COVID-19. “These findings have wide implications given that 40 percent of the global population is overweight or obese,” Dr Short said.
Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market, the latest Enforcement Report by the USFDA said. The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary. The USFDA cited cross-contamination with other products as the reason for the company recalling the product.